HMGCR loss is synthetic lethal with PIK3CD inhibition in colorectal cancer cells

Figure 4 Atorvastatin combined with gefitinib enhanced the inhibition of tumorigenesis in mice. A: The photograph shows that compared with atorvastatin or gefitinib alone, the combination of atorvastatin and gefitinib inhibited tumor formation in mice; B: Compared with atorvastatin or gefitinib alone, the combination of atorvastatin and gefitinib inhibited tumor weight; C: Compared with atorvastatin or gefitinib alone, the combination of atorvastatin and gefitinib inhibited tumor volume; D: The hematoxylin and eosin staining results showed that there was no obvious damage to the heart, lungs and liver of mice; E: There were no significant differences in liver function markers (alanine aminotransferase, aspartate aminotransferase) or creatinine levels between the control and treatment groups, indicating a favorable safety profile; F: KI67 staining showed that the combination of atorvastatin and gefitinib inhibited tumor proliferation; G: Immunofluorescence results showed that the number of LC3 fluorescence spots increased and P62 reduced following atorvastatin and gefitinib treatment. Data are presented as the mean ± SD. ^aP < 0.05, ^bP < 0.001. NS: Not significant; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; CREA: Creatinine.